Hépato-Gastro & Oncologie Digestive
Agenda
Volume 32, supplement 1, March 2025
The arrival of anti-IL23 is becoming clearer
Numéro réalisé avec le soutien institutionnel des laboratoires Lilly et Mayoly
Volume 32, supplement 1, March 2025
ÉDITORIAL
Anti-IL23s on the way
(p.4-5)
Xavier Roblin, Mathilde Barrau
MINI-REVUES
The long-awaited arrival of biologics targeting IL-23 in the management of Inflammatory Bowel Disease
(p.6-18)
Xavier Roblin, Mathilde Barrau, Cyrielle Mallard, Stéphane Nancey
PROs in IBD and their impact on quality of life
(p.19-26)
Xavier Hébuterne, Éric Balez
Towards new therapeutic targets in IBD
(p.27-31)
Mathurin Fumery, Clara Yzet
Crossed views on the role of ustekinumab in Crohn’s disease in french, european and american guidelines
(p.32-6)
Guillaume Bouguen